Griseofulvin 387mg/5ml oral solution
Requires a prescription from a doctor or prescriber
An antifungal antibiotic.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Griseofulvin
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Griseofulvin
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Part of the Grisol brand family (generic: Griseofulvin)
MHRA licensed products
View all licensed products for Griseofulvin on the MHRA register
WHO defined daily dose (DDD)
500 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary BNF/ATC mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 8 · Randomised trials: 2 · 1949–2022
Showing the 50 most relevant studies, sorted by most relevant.
David Fleece, John P. Gaughan, Stephen C. Aronoff
PEDIATRICS, 2004
- Terbinafine
- Antifungal Agents
- Griseofulvin
Hong Liang Tey, Andy S.L. Tan, Yuin Chew Chan
Journal of the American Academy of Dermatology, 2011
- Terbinafine
- Antifungal Agents
- Griseofulvin
Sandy Ong, Long Chiau Ming, Kah Seng Lee, et al.
Pharmaceutics, 2016
Clare M. Smith, Ante Jerkovic, Thy T. Truong, et al.
Scientific Reports, 2017
- Antifungal Agents
- Erythrocytes
- Ferrochelatase
Asger B. Petersen, Mads H. Rønnest, Thomas Ostenfeld Larsen, et al.
Chemical Reviews, 2014
- Antifungal Agents
- Griseofulvin
- Stereoisomerism
W. L. Chiou, S. Riegelman
Journal of pharmaceutical sciences, 1969
- Dosage Forms
- Griseofulvin
- Biopharmaceutics
Stephen E. Malawista, Hidemi Sato, Klaus G. Bensch
Science, 1968
- Annelida
- Birefringence
- Colchicine
J. C. Gentles
Nature, 1958
- Fungicides, Industrial
- Griseofulvin
- Tinea
Fernando Cabral, Mark E. Sobel, Michael M. Gottesman
Cell, 1980
- Cell Line
- Cell Membrane Permeability
- Colchicine
Robert G. Crounse
Journal of Investigative Dermatology, 1961
- Diet
- Fats
- Intestinal Absorption
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
9-21 hours
Mechanism
Griseofulvin is fungistatic, however the exact mechanism by which it inhibits the growth of dermatophytes is not clear.
Food interactions
2 warnings
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
25 to 70%
Half-life
9-21 hours
Metabolism
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 242 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Proteins and enzymes this drug interacts with in the body
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC D01BA01
ATC D01AA08
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Griseofulvin
Additional database identifiers
Drugs Product Database (DPD)
8569
ChemSpider
389934
BindingDB
31775
ZINC
ZINC000000622123
UniProt Accession
TBB_TRIRU
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6414
GeneCards
KRT12
UniProt Accession
K1C12_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2596
GenAtlas
CYP1A2
GeneCards
CYP1A2
GenBank Gene Database
Z00036
Guide to Pharmacology
1319
UniProt Accession
CP1A2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2637
GenAtlas
CYP3A4
GeneCards
CYP3A4
GenBank Gene Database
M18907
Guide to Pharmacology
1337
UniProt Accession
CP3A4_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
Linked open data from Wikidata (Q416096), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.